SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity (2020 - 2026)
SAB Biotherapeutics (SABS) posted Liabilities and Shareholders Equity of $238.21 million for Q2 2026, up 690.6% from $30.13 million a year earlier but down 4.1% from the prior quarter.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, SAB Biotherapeutics' Liabilities and Shareholders Equity came in at $172.81 million, up 291.0% from FY2024.
- Annual Liabilities and Shareholders Equity shows a five-year compound annual growth rate of 25.0% (FY2020 to FY2025).
- In prior years, SAB Biotherapeutics' Liabilities and Shareholders Equity was $44.2 million in FY2024 (-47.3%), $83.94 million in FY2023 (+64.9%), $50.9 million in FY2022 (-37.3%) and $81.14 million in FY2021 (+43.5%).
- Quarterly Liabilities and Shareholders Equity has run from a low of $28.34 million in Q3 2023 to a high of $248.47 million in Q1 2026 over five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased in each of the last four quarters, with growth averaging 214.9% over the last eight quarters.
- The strongest year-over-year quarter for Liabilities and Shareholders Equity in the past five years was Q2 2026, with growth of 690.6%; the weakest was Q3 2022, with a decline of 55.1%.
- According to Business Quant data, Liabilities and Shareholders Equity for the three prior quarters was $248.47 million (Q1 2026), $172.81 million (Q4 2025) and $183.45 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | SAB Biotherapeutics | 264.67 Mn | 264.67 Mn | - | 238.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 238.21 Mn |
| Mar 31, 2026 | 248.47 Mn |
| Dec 31, 2025 | 172.81 Mn |
| Sep 30, 2025 | 183.45 Mn |
| Jun 30, 2025 | 30.13 Mn |
| Mar 31, 2025 | 38.12 Mn |
| Dec 31, 2024 | 44.20 Mn |
| Sep 30, 2024 | 53.80 Mn |
| Jun 30, 2024 | 61.89 Mn |
| Mar 31, 2024 | 71.37 Mn |
| Dec 31, 2023 | 83.94 Mn |
| Sep 30, 2023 | 28.34 Mn |
| Jun 30, 2023 | 35.44 Mn |
| Mar 31, 2023 | 42.67 Mn |
| Dec 31, 2022 | 50.90 Mn |
| Sep 30, 2022 | 52.51 Mn |
| Jun 30, 2022 | 59.41 Mn |
| Mar 31, 2022 | 68.49 Mn |
| Dec 31, 2021 | 81.14 Mn |
| Sep 30, 2021 | 116.93 Mn |
API Access
SAB Biotherapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();